New Releases

Premium

Clarient announced the launch of its new epidermal growth factor receptor mutation test to help physicians select the right treatment for non-small cell lung cancer patients.

The laboratory-developed test analyzes formalin-fixed, paraffin-embedded tissue samples and detects EGFR mutations to help determine which NSCLC patients will respond to tyrosine kinase inhibitor treatments. The RT-PCR assay detects "the most common mutations of the EGFR gene," according to the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.